Potentially, the induction of myeloid leukaemia cells to differentiate into phenotypes possessing the characteristics of normal leucocytes with an abolished or reduced capacity to proliferate provides an alternative to conventional methods of treatment for this disease. A variety of agents have been shown to induce in vitro maturation of human acute myeloid leukaemia cells (Koeffler, 1983; Gabrilove, 1986) but none have been proven to possess therapeutic value. Differentiation inducing factor (DIF) is a lymphokine closely related to the colony stimulating factors (CSFs), which is released by mitogen stimulated human leucocytes, and which shares extensive amino acid homology with tumour necrosis factor (TNF) (Takeda et al., 1986) . Both DIF (Olsson et al., 1984) and recombinant human TNF (rhTNF) (Trinchieri et al., 1986) stimulate in vitro maturation of HL60 cells, a human myeloblastic cell line (Collins et al., 1977) . It is of interest to determine whether the differentiation inducing properties of TNF are retained in vivo. In this study we (Clutterbuck et al., 1985) (1986). Dual esterase staining showed these cells to possess cytoplasmic non-specific esterase (NSE) but not chloroacetate esterase, and thus to be of monocyte/macrophage phenotype. At a concentration of 1 U ml-rhTNF 16% of cells contained detectable NSE compared with < 1% in control cultures. Concomitant with the acquisition of NBT reducing ability was a decrease in cell number, with maximum inhibition of proliferation observed at 100 U ml-1 rhTNF. During the 6-day incubation period cell viability remained at >90% in all cultures. We investigated the effect of preincubation with rhTNF on the clonogenicity of HL60 cells in semi-solid culture and their ability to form tumours in immune-deprived mice. Cells were grown for 4 days in the presence or absence of 2 x 103 U ml1 rhTNF. The results of these experiments are shown in Table I . In two experiments rhTNF incubation reduced plating efficiency to 20% and 25% of the control values as estimated by the scoring of day 14 colonies. This was reflected in a reduction in the ability of subcutaneous implants of 2 x 106 washed viable cells to form tumours. In the first experiment 100% of cell inoculi from control cultures had produced palpable tumours 12 days after implant, whereas no tumours had arisen from the R.D. CLUTTERBUCK et al. implants of cells incubated with rhTNF (five mice with 10 implants per group). However, tumour formation was not completely inhibited by incubation with rhTNF, and by day 18 post-implant 100% of these inoculi had also produced tumours. The mean volume of these tumours remained at approximately 50% of that for control tumours until the experiment was stopped (day 34). In the second experiment tumour take-rate was again similar (control, 7/8; rhTNF, 6/8: four mice per group), with the appearance of palpable tumours being delayed by approximately 4 days by preincubation with rhTNF. Twenty-eight days after implant tumours established from rhTNF cultures had attained a mean volume of only 22% of that for control tumours.
Repeated daily administration of 2 x 106 U kg-1 rhTNF in two experiments produced no observable modification of the growth of HL60 tumours pre-established in immunedeprived mice (data not shown). At the termination of the first experiment, 3 days after cessation of rhTNF dosing, both control and treated tumour volumes had increased approximately 8-fold above that of their pretreatment volumes. The second experiment showed tumours to be similarly unresponsive to rhTNF and was terminated 24h after the final injection of rhTNF. Tumours from both control and treated groups were excised at this time and examined histologically. Cells remained predominantly blastlike with only the occasional cell possessing a banded or lobed nucleus (<1 %), with no difference being observed under light microscopy between control and treated groups. Cytochemical staining of frozen sections revealed no difference between control and treated tumours in numbers of cells staining positive for NSE. Cell suspensions made by the mechanical disaggregation of pooled tumour tissue from four control or four treated mice contained similar proportions of viable cells; 42% and 43%, respectively, as assessed by trypan blue exclusion. These cell suspensions also contained similar proportions of cells with NBT reducing activity; 6% and 8%, respectively. Femoral CFU-S contents in these mice were assayed according to the method of Till & McCulloch (1961) . The mean CFU-S content per femur in four mice treated with rhTNF was 275 (standard error 48), compared with 1,375 ±210 in four control animals (P<0.01).
Despite this reduction in haemopoietic stem cell numbers a rapid increase in peripheral blood leucocyte count was observed in rhTNF treated mice, as has been reported in patients treated with this cytokine (Selby et al., 1987) . Transient reductions in body weight (approximately 5% below that of control mice) were also observed in rhTNF treated animals.
Although the effects on normal tissues indicate that rhTNF at the dose used was active in vivo, it is possible that HL60 tumours received insufficient levels of cytokine to induce maturation or inhibit proliferation. However, in tumour bearing mice treated with 1 x 106 U kg 1 rhTNF (50% of the dose used in our experiments), plasma levels of rhTNF remained above 10OUml-m for 5h following i.p. injection (T. Shiga, personal communication). We also investigated the response to rhTNF of xenografts established from a population of primary AML cells (EK.AML). These tumours were responsive to the treatment regimen of 7 daily injections of 2 x 106 Ukg-1 rhTNF (Figure 2 ). The slope of the growth curve of rhTNF treated tumours was significantly less than that of control tumours (Student's t test, P<0.01). Individual cell suspensions made 24h after the last treatment in a repeat experiment contained mean viabilities of 55% (n = 4) in the untreated group and 8% (n = 5) in the treated group. Such low fractions of viable cells from tumours treated with rhTNF precluded cytochemical analysis. The effects on body weight and leucocyte count were similar to those described for HL60 tumour bearing mice. EK.AML cells failed to proliferate in continuous suspension culture, and so a direct comparison of the responses in vitro between these cells and HL60 cells was not possible.
The effect of recombinant human granulocyte/macrophage colony stimulating factor (rhGM-CSF) on rhTNF induced HL60 cell differentiation in vitro was investigated. rhGM-CSF (Sandoz) alone stimulated proliferation of HL60 cells (Figure 3 ). This effect was dose-dependent. No increase was seen in the number of cells with NBT reducing activity (data not shown), despite previous reports that HL60 cell differentiation was induced by GM-CSF (Tomonoga et al., 1986; Begley et al., 1987) . The inhibition of growth produced by rhTNF was partially reversed by rhGM-CSF (Figure 3b ) with a concomitant decrease in proportions of cells with NBT reducing activity (Figure 3c ). This observation is probably comparable with the modulation of the inhibitory action of rhTNF on human CFU-GM growth stimulated by CSF from different sources (Munker & Koeffler, 1987) . EGF, TGF-x and TGF-f have also been shown to interfere with the in vitro antiproliferative effects of rhTNF (Sugarman et al., 1987) .
These results demonstrate an anti-leukaemic effect of rhTNF against human EK.AML xenografts, but at a dose which produces plasma levels that are higher than those safely attainable in man (Selby et al., 1987) . rhTNF activity against HL60 cells in vitro was not reproduced in vivo, possibly due in part to the presence of other growth factors. Cells from many AML patients produce their own CSFs (Young et al., 1988) and may thus be rendered less susceptible to the antiproliferative/differentiative effects of rhTNF.
